home | Hanmi Pharmaceutical co., ltd.

Products Search

Product Search

R&D No.1: R&D No.1
Contribute to human health: Dedication to promote human health | Hanmi Pharmaceutical devotes to promote human health and to serve corporate social responsibility.

News Centermore

Athenex Announces Positive Recommendation by the Drug Safety Monitoring Board Upon the Second Interim Analysis and to Continue the Oraxol Phase III Program. Sep 07, 2018
Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer. Sep 07, 2018
Spectrum “Rolontis to confirm efficacy and safety…provide new treatment options” Jul 02, 2018
'Poziotinib' Data Published in SCI Journal 'Nature Medicine' Apr 24, 2018
Sanofi "Hanmi's efpeglenatide, to be added two new phase 3 clinical trials" Feb 08, 2018

Highlightsmore

Promotional videoHanmi Pharmaceuticals is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products

R&D

LAPSCOVERY

Novel platform technology for biologics, Long Acting Protein / Peptide Discovery
BIO Discovery

Biomedicine for maximizing treatment interval and efficiency
NCE Discovery

Next generation targeted oncology, autoimmune & metabolic diseases

Global Products자세히

2017 Product Development Portfolio

Explore our clinical development programs

Hanmi at a glance

No 1. R&D Company for global new drug development

Compliance program

Compliance system and code of conduct